Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702617 | 0.85 | MMP13 (0.41) | MMP13GSK3BPTGER4 | |
| SCHEMBL6704900 | 0.82 | MMP13 (0.49) | MMP13CDK2GSK3BEPHX2TRPA1 | |
| SCHEMBL6819967 | 0.82 | MMP13 (0.39) | MMP13GSK3BPTGER4 | |
| SCHEMBL6819953 | 0.81 | MMP13 (0.38) | MMP13GSK3BPTGER4 | |
| SCHEMBL6819957 | 0.80 | NPC1 (0.46) | MMP13GSK3B | |
| SCHEMBL6696733 | 0.79 | MMP13 (0.49) | MMP13CDK2GSK3BEPHX2TRPA1 | |
| SCHEMBL6813882 | 0.74 | MMP13 (0.44) | MMP13CDK2GSK3BEPHX2TRPA1 | |
| SCHEMBL6292169 | 0.72 | MMP13 (0.50) | MMP13CDK2GSK3BNR1H4 | |
| SCHEMBL6348866 | 0.71 | MMP13 (0.51) | MMP13CDK2GSK3BEPHX2TRPA1 | |
| SCHEMBL6698886 | 0.71 | MMP13 (0.51) | MMP13CDK2GSK3BEPHX2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885CDK2 84/4885GSK3B 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.